The global infectious disease testing market size was valued at USD 24.2 billion in 2022. It is projected to reach USD 41.5 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2023–2031).
Using test instruments and kits, infectious disease testing looks for the presence of foreign antigens or organisms. Most of the testing equipment and kits on the market are for bacterial and viral infections. It is anticipated that most of these testing kits will be replaced by molecular techniques. The market is expanding due to improvements in treating viral infections, the government's active involvement, and rising demand for new research techniques to track infectious diseases. The increased prevalence of infectious diseases, the shift in emphasis from centralized laboratories to point-of-care testing, and rising research and development spending in infectious disease diagnostics are all significant market-expanding factors.
Rapid diagnostics for disease identification are developing as a result of scientific research and development efforts to develop ground-breaking technologies and techniques like mass spectrometry and next-generation sequencing (NGS), which are assisting the growth of the infectious disease diagnostics market. The development of a fully automated process results from integrating technology with the current manual operations. Due to the rising adoption of molecular diagnostic technologies, the market for global infectious disease molecular diagnostics tests currently exhibits a high level of promise. The rising incidence rates of infectious diseases around the globe additionally boost the market.
POC diagnosis has become an essential component of patient-centric healthcare because of benefits like quick turnaround times and the ability to make treatment decisions immediately. Improvements in patient care have resulted from a preference shift from centralized to decentralized point-of-care testing for infectious diseases. The market is driven by the market participants' willingness to supply POC products to remote locations due to the rising demand for quick tests. For instance, ID NOW, the quickest molecular point-of-care test created by Abbott, provides quick results for COVID-19 in less than 13 minutes and is used in various decentralized healthcare settings, including doctor's offices and urgent care centers. Therefore, the adoption of rapid diagnostic testing in decentralized healthcare settings makes these devices easily accessible to personnel with less training and does away with the need for sample transportation to the core labs. The factors mentioned earlier are expected to hasten the development of infectious disease point-of-care diagnostics.
Major players in the infectious disease diagnostics market are anticipated to have opportunities for growth in emerging economies like India, South Korea, Brazil, and Mexico. This can be attributed to the high disease prevalence, sizable patient population, expanding medical tourism, improved healthcare infrastructure, and rising disposable income in these nations. The Asia Pacific region has become a flexible and business-friendly hub thanks to less onerous regulations and data requirements than the previously mentioned factors. The market is driven by an increase in external funding for clinical studies involving infectious disease molecular diagnostics. In the process of developing a product, funding is crucial.
Most people worldwide who have infectious diseases like HIV, malaria, and tuberculosis live in developing nations. Lack of clinician training and poor product accessibility brought on by lower per capita spending has resulted in a decline in the use of POC kits in low- and middle-income countries. For instance, 420 clinician respondents in Africa were surveyed by the National Centre for Biotechnology Information (NCBI), and it was reported that more than 30% of the clinicians lacked the necessary training to conduct point-of-care diagnostic tests. This leads to incorrect results interpretation, which reduces the test's accuracy. Consequently, it is likely to impede market expansion.
The prevalence of diseases like HIV, influenza, RSV, and others is rising globally, which increases the rate at which patients are diagnosed. For instance, the United Nations Program on HIV/AIDS (UNAIDS) estimates that 38 million people worldwide have received an HIV/AIDS diagnosis. Additionally, a different report released by the World Health Organization (WHO) estimates that approximately 10 million people worldwide were affected by tuberculosis. As a result, during the forecast period, the increasing prevalence of infectious diseases will increase the demand for point-of-care products for their diagnosis and consequently support market growth.
The market is segmented by product & services, technology, and end user.
Based on products & services, the global infectious disease testing market is bifurcated into kits & reagents, instruments, and software.
The kits & reagents segment is the highest contributor to the market and is expected to grow at a CAGR of 6.54% during the forecast period. Due to the rise in PCR reagent demand, the number of novel reagent launches has increased exponentially. Due to increased research and development (R&D) activities in the pharmaceutical and biotechnology industries, a rise in reagent demand, and a surge in the use of point-of-care testing. However, the instruments market is anticipated to expand significantly over the forecast period due to increased research laboratories and funding from public and private organizations to create diagnostic tools for the pharmaceutical and biotechnology sectors.
Based on technology, the global infectious disease testing market is bifurcated into immunodiagnostics, DNA sequencing & NGS, and PCR.
The DNA sequencing & NGS segment is the highest contributor to the market and is expected to grow at a CAGR of 6.19% during the forecast period. NGS's expanding applications and the development of sequencing technologies fuel market expansion. NGS has the potential to expedite early disorder detection and the discovery of pharmacogenetic markers to individualize treatment. The three crucial stages of all NGS procedures are library preparation, assay design, and data analysis. The New York State Department of Health uses whole-genome sequencing to treat viral infections like influenza in the United States.
Based on end users, the global infectious disease testing market is bifurcated into hospitals/ clinical laboratories, reference laboratories, physician offices, and academic/research institutes.
The hospitals/ clinical laboratories segment is the highest contributor to the market and is expected to grow at a CAGR of 6.7% during the forecast period. The hospital bedside segment is anticipated to hold a commanding market share during the forecast period. The rise in hospital stays by patients with infectious diseases is to blame for its dominance. The need for infectious disease point-of-care diagnostics in hospital settings has ultimately increased. They offer quick test results, are easily accessible, and offer flexibility in terms of when specimen pickups should occur. The development of advanced diagnostic tests, growing Medicare reimbursement, and an aging population contribute to the segment's expansion.
COVID-19 has resulted in the introduction of several new testing methods with high accuracy at lower prices. On April 1, 2020, The Association of British HealthTech Industries (ABHI), BioIndustry Association (BIA), and the British In-Vitro Diagnostic Association (BIVDA) announced a global need for components of testing kits to ensure its supply in the healthcare sector. In South Korea, mass testing is conducted to identify the people affected by COVID-19. Moreover, laboratory tests provide better accuracy than testing kits. The manufacturers are channelizing efforts to develop advanced testing kits and adopting new strategies to reduce the cost and attain authorization from the government.
The global infectious disease testing market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant shareholder in the global infectious disease testing market and is expected to grow at a CAGR of 5.93% during the forecast period. The U.S. and Canada are included in the analysis of the infectious disease testing market in North America. Due to its top-tier national clinical laboratories, well-developed healthcare systems, and simple access to cutting-edge technology, North America dominates the market for infectious disease testing. The next-generation sequencing technology is currently a novel development for infectious disease testing, and clinical laboratories are concentrating on it. Due to the coronavirus, there has been a shortage of testing kits in the United States. Therefore, new technologies for gene sequencing and diagnostic testing are actively being developed by pathologists and clinical laboratories. The USFDA is also making significant efforts to create practical diagnostic tools for genetic diseases. It has established a public database with details on genes, genetic variants, and their connections to infectious diseases.
Asia Pacific is expected to grow at a CAGR of 6.68% during the forecast period. China, Australia, India, Japan, and the rest of Asia-Pacific are all included in the Asia-Pacific infectious disease testing market analysis. Due to increasing urbanization, which creates an unhygienic environment in cities, emerging economies like India and China are the primary consumers of infectious disease testing. Due to the high prevalence and incidence of infectious diseases, particularly bacterial infections and sexually transmitted diseases, countries in the Asia-Pacific and African regions hold the largest market for infectious disease diagnosis. Especially in the Asia Pacific, the healthcare sector is proliferating, making it simpler to put advanced molecular diagnostics labs and equipment into place. Positive developments like government-sponsored healthcare raised public awareness, and the desire to receive top-notch medical care is also anticipated to propel the market.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|